These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30720546)

  • 21. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.
    Picard M; Castells MC
    Clin Rev Allergy Immunol; 2015 Oct; 49(2):177-91. PubMed ID: 24740483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer.
    Ruggiero A; Triarico S; Trombatore G; Battista A; Dell'acqua F; Rizzari C; Riccardi R
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1739-46. PubMed ID: 23765411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
    Laird CM; Glode AE; Schwarz K; Lam ET; O'Bryant CL
    J Oncol Pharm Pract; 2020 Sep; 26(6):1369-1373. PubMed ID: 31955703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs.
    Bermingham WH; Bhogal R; Arudi Nagarajan S; Mutlu L; El-Shabrawy RM; Madhan R; Krishnaswamy UM; Murali MR; Kudagammana ST; Shrestha R; Sumantri S; Christopher DJ; Mahesh PA; Dedicoat M; Krishna MT
    Clin Exp Allergy; 2022 Mar; 52(3):375-386. PubMed ID: 34939251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk assessment of antibiotic residues of beta-lactams and macrolides in food products with regard to their immuno-allergic potential.
    Dewdney JM; Maes L; Raynaud JP; Blanc F; Scheid JP; Jackson T; Lens S; Verschueren C
    Food Chem Toxicol; 1991 Jul; 29(7):477-83. PubMed ID: 1894215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
    Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
    Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclo-oxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase.
    Bakhriansyah M; Meyboom RHB; Souverein PC; de Boer A; Klungel OH
    Fundam Clin Pharmacol; 2019 Oct; 33(5):589-600. PubMed ID: 30860620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
    Yun H; Xie F; Beyl RN; Chen L; Lewis JD; Saag KG; Curtis JR
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1526-1534. PubMed ID: 27813327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation and management of hypersensitivity to proton pump inhibitors.
    Bose S; Guyer A; Long A; Banerji A
    Ann Allergy Asthma Immunol; 2013 Dec; 111(6):452-7. PubMed ID: 24267357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypersensitivity Reactions to Multiple Iodinated Contrast Media.
    Doña I; Bogas G; Salas M; Testera A; Moreno E; Laguna JJ; Torres MJ
    Front Pharmacol; 2020; 11():575437. PubMed ID: 33071787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
    Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
    Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Hypersensitivity Reactions to Nondextran Iron Products: New Insights Into Predisposing Risk Factors.
    Steveling-Klein EH; Mateluna CM; Meienberg A; Hartmann K; Bircher A; Scherer Hofmeier K
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2406-2414.e2. PubMed ID: 33486145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactions to cytostatic agents in children.
    Cernadas JR
    Curr Opin Allergy Clin Immunol; 2017 Aug; 17(4):255-261. PubMed ID: 28622171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on adverse drug reactions related to β-lactam antibiotics.
    Vardakas KZ; Kalimeris GD; Triarides NA; Falagas ME
    Expert Opin Drug Saf; 2018 May; 17(5):499-508. PubMed ID: 29633867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.
    Bager P; Hvas CL; Dahlerup JF
    Br J Clin Pharmacol; 2017 May; 83(5):1118-1125. PubMed ID: 27859495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
    Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
    J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions.
    Otani IM; Lax T; Long AA; Slawski BR; Camargo CA; Banerji A
    J Allergy Clin Immunol Pract; 2018; 6(4):1266-1273.e2. PubMed ID: 28986119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
    Lansinger OM; Biedermann S; He Z; Colevas AD
    J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.